<DOC>
	<DOCNO>NCT00730197</DOCNO>
	<brief_summary>The objective study investigate bioequivalence nisoldipine extended-release 40 mg tablet ( Mylan Pharmaceuticals Inc. ) Sular® Extended-Release 40 mg tablet ( manufacture First Horizon ) follow single , oral 40 mg ( 1 × 40 mg tablet ) dose administration healthy adult subject fasting condition .</brief_summary>
	<brief_title>Fasting Bioequivalence Study Nisoldipine Extended-Release Tablets 40 mg</brief_title>
	<detailed_description />
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Nisoldipine</mesh_term>
	<criteria>I . Subjects meet follow criterion include study . 1 . Age : 18 year old . 2 . Sex : Male and/or nonpregnant , nonlactating female . 1 . Women childbearing potential negative serum beta human chorionic gonadotropin ( βHCG ) pregnancy test perform within 21 day prior start study even prior dose administration . An additional serum ( βHCG ) pregnancy test perform upon completion study . 2 . Women childbearing potential require practice abstinence use acceptable form contraception throughout duration study . No hormonal contraceptive hormonal replacement therapy permit study . Acceptable form contraception include following : 1. intrauterine device place least 3 month prior start study remain place study period , 2. barrier method contain use conjunction spermicidal agent , 3. surgical sterilization ( tubal ligation , oophorectomy hysterectomy ) postmenopausal accompany document postmenopausal course least one year . 3 . Women consider childbearing potential one follow report documented medical history : 1. postmenopausal absence menses least one ( 1 ) year , 2. bilateral oophorectomy without hysterectomy absence bleed least 6 month , 3. total hysterectomy 4 . During course study , study screen study exit include washout period , men woman childbearing potential must use spermicide contain barrier method contraception addition current contraceptive method . 3 . Weight : At least 60 kg ( 132 lb ) men 48 kg ( 106 lb ) woman subject Body Mass Index ( BMI ) less equal 30 great equal 19 . 4 . All subject judge normal healthy prestudy medical evaluation , ( physical examination , laboratory evaluation , Hepatitis B Hepatitis C test , HIV test , 12lead ECG , urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiates , phencyclidine , methadone ) perform within 21 day initial dose study medication . II . Subjects meet follow criterion exclude study : 1 . Institutionalized subject use . 2 . Social Habits : 1 . Use tobaccocontaining product within 1 year prior dose . 2 . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . 3 . Ingestion vitamins herbal product within 7 day prior initial dose study medication . 4 . Any recent , significant change dietary exercise habit . 5 . A positive test drug include urine drug screen . 6 . History drug and/or alcohol abuse . 3 . Medications : 1 . Use prescription overthecounter ( OTC ) medication within 14 day prior initial dose study medication . 2 . Use hormonal contraceptive hormone replacement therapy within 3 month prior study medication dosing . 3 . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . 4 . Diseases : 1 . History significant cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic disease . 2 . Acute illness time either prestudy medical evaluation dosing . 3 . A positive HIV , hepatitis B , hepatitis C test . 5 . Abnormal clinically significant laboratory test result : 1 . Clinically significant deviation Guide Clinically Relevant Abnormalities 2 . Abnormal clinically relevant ECG tracing . 6 . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . 7 . Subjects receive investigational drug within 30 day prior initial dose study medication . 8 . Allergy hypersensitivity nisoldipine , inactive ingredient , calcium channel blocker product . 9 . History difficulty swallow , gastrointestinal disease could affect drug absorption . 10 . Consumption grapefruit grapefruit containing product within 7 day drug administration . 11 . Average sit pulse rate le 55 beat per minute five minute rest screen prior Period I Day 1 dosing . Pulse rate measurement take triplicate least two ( 2 ) minute elapse inbetween reading . 12 . Average sit systolic blood pressure le 90 mmHg average sit diastolic blood pressure le 60 mmHg follow five ( 5 ) minute rest screen prior Period I Day 1 dosing . Blood pressure measurement take triplicate least two ( 2 ) minute elapse inbetween reading .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>